Tscan Therapeutics Inc’s filing revealed that its 10% Owner Lynx1 Capital Management LP acquired Company’s shares for reported $1.67 million on May 19 ’25. In the deal valued at $1.20 per share,1,388,794 shares were bought. As a result of this transaction, Lynx1 Capital Management LP now holds 6,746,141 shares worth roughly $14.91 million.
Then, Lynx1 Capital Management LP bought 1,200,000 shares, generating $1,440,000 in total proceeds. Upon buying the shares at $1.20, the 10% Owner now owns 7,946,141 shares.
Before that, Lynx1 Capital Management LP bought 100,000 shares. Tscan Therapeutics Inc shares valued at $290,140 were divested by the 10% Owner at a price of $2.90 per share. As a result of the transaction, Lynx1 Capital Management LP now holds 5,357,347 shares, worth roughly $11.84 million.
BTIG Research initiated its Tscan Therapeutics Inc [TCRX] rating to a Buy in a research note published on May 16, 2024; the price target was $12. A number of analysts have revised their coverage, including Needham’s analysts, who began to cover the stock in mid May with a ‘”a Buy”‘ rating. Wedbush began covering TCRX with “an Outperform” recommendation on June 22, 2023.
Price Performance Review of TCRX
On Friday, Tscan Therapeutics Inc [NASDAQ:TCRX] saw its stock jump 1.84% to $2.21. Over the last five days, the stock has gained 4.74%. Tscan Therapeutics Inc shares have fallen nearly -60.47% since the year began. Nevertheless, the stocks have fallen -27.30% over the past one year.
How much short interest is there in Tscan Therapeutics Inc?
A steep rise in short interest was recorded in Tscan Therapeutics Inc stocks on 2025-09-30, dropping by -0.14 million shares to a total of 1.57 million shares. Yahoo Finance data shows the prior-month short interest on 2025-08-29 was 1.71 million shares. There was a decline of -9.14%, which implies that there is a negative sentiment for the stock.